Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New lens implant aims to sharpen vision at all distances

NCT ID NCT06401551

Symptom relief Sponsor: Alcon Research Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a newer trifocal lens implant (Clareon PanOptix Pro) against an older one (Clareon PanOptix) in 71 adults having cataract surgery in both eyes. Each person got one of each lens, so their eyes could be compared directly. The goal was to see if the newer lens provides better distance, intermediate, and near vision without glasses.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
intraocular lens (IOL) implant
What this could lead to
If the newer lens works better, it could offer sharper vision at all distances after cataract surgery, reducing the need for glasses.
What could go wrong
This is a small, completed study with only 71 people. The improvement may be small or not noticeable for everyone. As with any eye surgery, risks include infection or inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

71 people

The number who actually took part.

Started

Jun 2024

Finished

Apr 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

22 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Understand and sign an ethics committee-approved informed consent form; * Willing and able to attend all scheduled study visits as required by the protocol; * Planned cataract surgery (both eyes); * Preoperative corneal astigmatism less that 1.00 diopter in each eye. * Other protocol-defined inclusion criteria may apply. Key Exclusion Criteria: * Women of childbearing potential if currently pregnant, intend to become pregnant during the study, or are breastfeeding; * Ocular conditions as specified in the protocol; * Subjects who desire monovision correction. * Other protocol-defined exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aphakia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Aphakia cataract congenital primary aphakia presbyopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aphakia Presbyopia

Contacts and locations

Locations

  • Carolina Eye Care Physicians

    Charleston, South Carolina, 29414, United States

  • Cincinnati Eye Institute

    Cincinnati, Ohio, 45242, United States

  • Grosinger, Spigelman & Grey Eye Surgeons, P.C.

    Bloomfield Hills, Michigan, 48302, United States

  • Houston Eye Associates

    Houston, Texas, 77008, United States

  • Moyes Eye Center

    Kansas City, Missouri, 64154, United States

  • The Eye Institute of Utah

    Salt Lake City, Utah, 84107, United States

  • Vision for Life

    Nashville, Tennessee, 37205, United States

  • Wolstan & Goldberg Eye Associates

    Torrance, California, 90505, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.